Pluri Inc. (PLUR) Spending and interest coverage
- R&D / revenue · 12 months: Value 1485.43%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 366.73%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 1485.43% | Research and development expense / revenue. Period ending 2026-06-30. $15.09M ÷ $1.02M × 100 ≈ 1485.43% |
| Stock-based compensation / revenue · 12 months | 366.73% | Share-based compensation / revenue. Period ending 2026-06-30. $3.73M ÷ $1.02M × 100 ≈ 366.73% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 15.09M USD | Research and Development Expense |
| Revenue | 1.02M USD | |
| Stock-based compensation | 3.73M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -24.94M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.09M | $1.02M | $3.73M | $-24.94M | (m) | 1485.43% | 366.73% | (m) | (m) |
| 2026-03-31 | $15.71M | $1.08M | $4.09M | $-26.01M | (m) | 1456.26% | 378.87% | (m) | (m) |
| 2025-12-31 | $14.79M | $1.34M | $3.44M | $-24.88M | (m) | 1104.85% | 257.06% | (m) | (m) |
| 2025-09-30 | $13.89M | $1.33M | $2.94M | $-23.33M | (m) | 1047.74% | 221.34% | (m) | (m) |
| 2025-06-30 | $12.85M | $1.34M | $2.14M | $-22.18M | (m) | 961.90% | 160.40% | (m) | (m) |
| 2025-03-31 | $12.25M | $1.03M | $1.90M | $-21.59M | (m) | 1184.91% | 183.37% | (m) | (m) |
| 2024-12-31 | $12.30M | $678.00K | $2.02M | $-21.72M | (m) | 1814.60% | 298.38% | (m) | (m) |
| 2024-09-30 | $12.34M | $598.00K | $2.34M | $-21.98M | (m) | 2063.88% | 391.30% | (m) | (m) |
| 2024-06-30 | $12.45M | $326.00K | $2.62M | $-22.16M | (m) | 3817.79% | 803.07% | (m) | (m) |
| 2024-03-31 | $14.24M | $341.00K | $3.06M | $-22.67M | $868.00K | 4176.25% | 897.95% | -26.12× | Reported |
| 2023-12-31 | $15.31M | $357.00K | $3.49M | $-24.23M | $867.00K | 4289.64% | 977.31% | -27.95× | Reported |
| 2023-09-30 | $16.28M | $254.00K | $3.83M | $-25.70M | $863.00K | 6407.87% | 1507.48% | -29.78× | Reported |
| 2023-06-30 | $17.41M | $287.00K | $3.98M | $-27.25M | $843.00K | 6067.25% | 1385.71% | -32.32× | Reported |
| 2023-03-31 | $18.81M | $176.00K | $4.07M | $-29.58M | (m) | 10688.64% | 2311.93% | (m) | (m) |
| 2022-12-31 | $20.75M | $323.00K | $5.75M | $-32.96M | (m) | 6424.77% | 1778.64% | (m) | (m) |
| 2022-09-30 | $22.72M | (m) | $6.71M | $-37.08M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $24.61M | $234.00K | $8.91M | $-41.59M | $887.00K | 10514.96% | 3807.26% | -46.89× | Reported |
| 2022-03-31 | $27.71M | (m) | $11.37M | $-47.30M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $29.26M | (m) | $14.17M | $-51.05M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $30.72M | (m) | $16.12M | $-53.33M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $30.53M | (m) | $13.97M | $-50.62M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $27.98M | (m) | $10.94M | $-44.55M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $25.90M | (m) | $5.79M | $-37.72M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $23.47M | (m) | $2.73M | $-31.02M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $23.10M | $23.00K | $2.56M | $-29.48M | (m) | 100417.39% | 11139.13% | (m) | (m) |
| 2020-03-31 | $23.40M | $23.00K | $3.20M | $-28.89M | (m) | 101756.52% | 13908.70% | (m) | (m) |
| 2019-12-31 | $26.08M | $23.00K | $4.58M | $-31.79M | (m) | 113404.35% | 19917.39% | (m) | (m) |
| 2019-09-30 | $27.94M | (m) | $4.68M | $-33.76M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $29.88M | $54.00K | $5.15M | $-35.53M | (m) | 55337.04% | 9529.63% | (m) | (m) |
| 2019-03-31 | $31.06M | $54.00K | $5.60M | $-36.38M | (m) | 57512.96% | 10374.07% | (m) | (m) |
| 2018-12-31 | $30.12M | $54.00K | $5.64M | $-35.13M | (m) | 55772.22% | 10437.04% | (m) | (m) |
| 2018-09-30 | $28.94M | $54.00K | $6.37M | $-35.26M | (m) | 53600.00% | 11800.00% | (m) | (m) |
| 2018-06-30 | $26.37M | $50.00K | $6.55M | $-33.73M | (m) | 52742.00% | 13096.00% | (m) | (m) |
| 2018-03-31 | $24.84M | (m) | $5.97M | $-31.54M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $23.94M | (m) | $5.86M | $-30.72M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $23.16M | (m) | $4.68M | $-28.90M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $24.00M | (m) | $3.66M | $-28.02M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $24.52M | (m) | $3.29M | $-27.61M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $23.74M | (m) | $2.41M | $-26.78M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $23.83M | (m) | $2.65M | $-24.36M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $22.86M | $2.85M | $3.07M | $-23.32M | (m) | 802.81% | 107.94% | (m) | (m) |
| 2016-03-31 | $22.54M | $2.94M | $3.51M | $-22.96M | (m) | 766.41% | 119.25% | (m) | (m) |
| 2015-12-31 | $22.93M | $3.04M | $3.87M | $-23.09M | (m) | 755.11% | 127.44% | (m) | (m) |
| 2015-09-30 | $22.74M | $379.00K | $3.90M | $-25.17M | (m) | 5999.74% | 1029.02% | (m) | (m) |
| 2015-06-30 | $23.42M | $379.00K | $4.05M | $-25.27M | (m) | 6178.36% | 1069.13% | (m) | (m) |
| 2015-03-31 | $23.75M | $379.00K | $4.58M | $-26.17M | (m) | 6267.02% | 1209.76% | (m) | (m) |
| 2014-12-31 | $24.45M | $379.00K | $5.27M | $-27.92M | (m) | 6452.51% | 1390.24% | (m) | (m) |
| 2014-09-30 | $25.18M | $379.00K | $5.74M | $-28.61M | (m) | 6643.01% | 1513.19% | (m) | (m) |
| 2014-06-30 | $24.94M | $379.00K | $5.85M | $-27.85M | (m) | 6579.95% | 1543.80% | (m) | (m) |
| 2014-03-31 | $25.54M | $380.00K | (m) | $-28.35M | (m) | 6720.00% | (m) | (m) | (m) |
| 2013-12-31 | $23.62M | $479.00K | (m) | $-25.00M | (m) | 4930.27% | (m) | (m) | (m) |
| 2013-09-30 | $21.66M | $579.00K | (m) | $-22.89M | (m) | 3740.07% | (m) | (m) | (m) |
| 2013-06-30 | $19.91M | $679.00K | (m) | $-22.22M | (m) | 2931.66% | (m) | (m) | (m) |
| 2013-03-31 | $16.31M | $685.00K | (m) | $-18.98M | (m) | 2381.31% | (m) | (m) | (m) |
| 2012-12-31 | $12.71M | $716.00K | (m) | $-15.03M | (m) | 1774.86% | (m) | (m) | (m) |
| 2012-09-30 | $13.59M | $757.00K | (m) | $-14.89M | (m) | 1795.38% | (m) | (m) | (m) |
| 2012-06-30 | $12.71M | $716.00K | (m) | $-15.03M | (m) | 1774.58% | (m) | (m) | (m) |
| 2012-03-31 | $11.75M | (m) | (m) | $-14.90M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $10.47M | (m) | (m) | $-12.99M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | $9.68M | (m) | (m) | $-13.69M | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $8.31M | (m) | (m) | $-11.11M | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $6.12M | (m) | (m) | $-7.44M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |